ETON Eton Pharmaceuticals, Inc. Insider Trading

CEO Sean Brynjelsen sells 120,000 shares ($3.8M) at $31.88; stock now down 14.6% from 52-week high despite +79.2% quarterly rally.

Sean Brynjelsen sold 120,000 shares—a 12.6% reduction in his holdings—in 2 separate transactions at prices of $31.88 and $32.67 on 2026-05-28, for a combined $3,825,716.92. The transaction occurred near the 52-week high, with the stock currently trading at $30.45, down 14.6% from its 52-week peak of $35.66 despite a +79.2% gain over 90 days. His prior sells at ETON show a mixed timing pattern: 3 of 5 prior same-ticker sales were well-timed at the 90-day mark (negative returns post-sale), but his cross-ticker track record shows an avg 90d return of -2.1% after 5 prior sells (60% well-timed rate). Against the backdrop of the company's fundamentals—recent quarter revenue of $24,266,000.00 ($24.3M), net income of $1,554,000.00 ($1.6M), but a full-year negative net income and +104.9% annual revenue growth—this substantial CEO sale at cyclical highs warrants attention to whether elevated valuation or forward guidance changes are driving the reduction.

ETON CBO David Krempa sells 100,000 shares (79.8% of non-derivative holdings) across 5 transactions at blended $32.30; retains 25,249 shares and 256,491 option shares.

David Krempa, Chief Business Officer of Eton Pharmaceuticals, executed 5 separate sales totaling 100,000 shares for $3,229,923.24 between May 22–27, 2026, at prices ranging from $31.49 to $35.00, realizing a blended average price of $32.30. The sales reduced his non-derivative holdings by 79.8%, from 125,249 to 25,249 shares, though he retains 256,491 shares in employee stock options across five distinct option vehicles. The sales occurred while the stock was up 38.2% over the prior 30 days and 87.8% over 90 days, and the company reported annual revenue growth of 104.9% year-over-year despite negative full-year net income. The large share reduction warrants scrutiny given the magnitude and the company's still-unprofitable status despite strong top-line growth, particularly as derivative holdings remain material to the executive's total position.